Thank you, Mr. Chair, and thank you to our many witnesses today.
This committee has looked at a number of issues revolving around COVID and the government response to it at the time. This far away from the initial crisis, we tend to forget what an uncertain time that was, how little we understood what we were dealing with, what the disease was, and how to effectively treat and conquer it. I think it's important to go back to that.
It's good that without knowing who the winners would be—because nobody knew what the effective vaccines were—you did not put all our eggs in one basket. We had seven different vaccines that we were investigating.
By the end of May 2022, the Public Health Agency reported that 82% of eligible people had received at least two doses. I think that's quite remarkable under the circumstances, but it's always good to compare.
Is there any one of you who could address—I don't know if it's Mr. Lucas—how that uptake compares with the uptake in similar countries, like the U.S., the U.K. or Germany?